Atom Investors’s Phathom Pharmaceuticals PHAT Stock Holding History

Atom Investors’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-10,394	Closed	-$65.2K	–	745
2025 Q1	$65.2K	Buy	+10,394	New	+$63.1K	0.01%	458
2023 Q3	–	Sell	-53,286	Closed	-$763K	–	493
2023 Q2	$763K	Sell	53,286 -33,321	-38%	-$384K	0.29%	72
2023 Q1	$618K	Buy	+86,607	New	+$761K	0.34%	79

Other funds holding PHAT

FLSM

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Atom Investors's PHAT Position: Q2 2025 in Review

Atom Investors sold out of Phathom Pharmaceuticals (PHAT) in Q2 2025, closing a stake of 10,394 shares — an estimated $65.2K sold.

Atom Investors first reported a position in PHAT in Q1 2023 and held it in 3 quarters. The position peaked at $763K in Q2 2023. 117 funds tracked by Wall St. Rank hold PHAT as of Q2 2025.

Atom Investors reported no remaining Phathom Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
Atom Investors sold 10,394 Phathom Pharmaceuticals shares in Q2 2025, an estimated $65.2K.
Atom Investors first reported a position in Phathom Pharmaceuticals in Q1 2023 and held it in 3 quarters.
Atom Investors's Phathom Pharmaceuticals position peaked at $763K in Q2 2023.
117 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2025.

Based on Atom Investors's 13F filing for Q2 2025, filed 14 Aug 2025.